Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, relative ease of synthesis, ready availability of low cost starting materials and general low toxicity. As a result, approximately 60 peptide-based drugs have been approved by the FDA, 140 peptidic drugs are currently under evaluation in clinical trials and a further 500 peptides are in development. Success stories include the prostate cancer drug Lupron™ from Abbott Laboratories, with global sales of more than US$2.3 billion in 2011. Understandably, research into the area of new peptide drugs is at an all-time high.
With synthesis visualization software, higher loading capacity in purification, and effective evaporation technology, Biotage has developed a suite of technology to support the whole peptide workflow.
Download the white paper below (PPS468)
Opioids: Choosing the Best Solution for your Laboratory
Notice of Discontinuation of Biotage ZIP® and Biotage ZIP® Sphere
An Environmental Chemist Speaks Out
Drugs of Abuse Urine Testing White Paper Updated to Include a Further 50 Analytes
Application Video 894: Extraction of Aldosterone and Angiotensin from Plasma